MPS I Registry

The MPS I Registry is an ongoing, observational database that tracks natural history and outcomes of patients with MPS I. It was initiated worldwide in April 2003 as an international observational registry program sponsored by BioMarin/Genzyme and administered by Genzyme Corporation.

As of May 2006, data from over 544 patients with MPS I have been collected from physicians in 27 countries.

ALL patients with a confirmed diagnosis of MPS I disease are eligible for inclusion in the MPS I Registry.

The MPS I Registry's goal is to significantly contribute to the medical understanding of MPS I disease and to improve the quality of care for MPS I patients worldwide through active publication of MPS I Registry findings and disease management approaches.

The primary objectives of the MPS I Registry are:

To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)

To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I

To help the MPS I medical community with development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care.

To learn more about the MPS I Registry or to enroll online, please visit www.mpsiregistry.com

You can also contact your local Genzyme representative or e-mail us for more information on the MPS I Registry or to order the MPS I Registry Annual Report.